A Phase 2 Study to Evaluate the Dosing and Timing of VGT-309, a Tumor-Targeted Fluorescent Imaging Agent for the Identification of Lung Cancer

TThis study aims to evaluate the efficacy and safety of VGT-309, a tumor-targeted imaging agent, when used intraoperatively in subjects scheduled for surgical resection or biopsy of suspicious or confirmed lung cancer.

Who is it for?
This study is for adult men and women aged 18 years and older who are scheduled to undergo surgical resection or excisional biopsy (as per standard care) of a lung nodule that is suspicious for, or confirmed to be, lung cancer.

Study Details
Eligible subjects will receive a single intravenous infusion of VGT-309, administered 36-96 hours preoperatively. Total participation will last approximately 35 days (excluding a 28-day screening period). During this time, subjects will undergo safety monitoring, including blood and urine sample collections, vital sign checks, physical examinations, and ECGs.

This research aims to enable doctors to use VGT-309 as an intraoperative fluorescent imaging agent to differentiate lung cancer from surrounding normal tissue in the future.